Health Care-Related Economic Burden of the Polycystic Ovary Syndrome during the Reproductive Life Span
The DOI matches its Crossref record; 89 of the 90 references it cites were found in a registry or an index.
Abstract
CONTEXT: The polycystic ovary syndrome (PCOS) is the most common endocrine abnormality of reproductive-aged women today, affecting approximately 6.6% of unselected reproductive-aged women (approximately 4 million women in the United States) (1990 National Institutes of Health criteria), and potentially represents a significant financial burden to our health care. OBJECTIVE: The objective of the study was to define, using current definitions and prevalence or incidence data, the minimal economic burden that PCOS in reproductive-aged women represents for the United States. DESIGN: The study design was a literature review. SETTING: The study was conducted at a tertiary care center. PATIENTS OR OTHER PARTICIPANTS: There were no patients or other participants. INTERVENTION(S): We performed a systematic review of the published medical literature to identify studies evaluating epidemiology of reproductive-age PCOS and its clinical consequences and costs. We tied general societal cost data for the different health consequences to reproductive-age PCOS costs, using prevalence data. MAIN OUTCOME MEASURE(S): The main measure in the study was total health care-related economic costs. RESULTS: We estimated the mean annual cost of the initial evaluation to be dollar 93 million (2.1% of total costs), that of hormonally treating menstrual dysfunction/abnormal uterine bleeding to be dollar 1.35 billion (31.0% of total), that of providing infertility care to be dollar 533 million (12.2% of total), that of PCOS-associated diabetes to be dollar 1.77 billion (40.5% of total), and that of treating hirsutism to be dollar 622 million (14.2% of total). CONCLUSIONS: The total cost of evaluating and providing care to reproductive-aged PCOS women in the United States is dollar 4.36 billion. Because the cost of the diagnostic evaluation accounted for a relatively minor part of the total costs (approximately 2%), more widespread and liberal screening for the disorder appears be a cost-effective strategy, leading to earlier diagnosis and intervention and possibly the amelioration and prevention of serious sequelae.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“comprehensive screening and counseling from physicians and greater public awareness can curtail morbidity and reduce the economic burden on both the patient and the healthcare system.”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [61]
In the citing paper
“PCOS has a high healthcare-related economic burden”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [61]
In the citing paper
“Also from a resource allocation perspective, the financial costs related to diagnosis of PCOS are only a small fraction (2%) of the total costs associated with comprehensive care for PCOS in the United States (32).”
From Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome (2016) · cites this paper as [32]
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712
Self-citationMen at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Amenorrhea associated with bilateral polycystic ovaries
Stein, I. F., & Leventhal, M. L. (1935) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(15)30642-6 · Cited by 2,121
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Knochenhauer, E. S., Key, T. J., Kahsar-Miller, M., Waggoner, W., Boots, L. R., & Azziz, R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5090 · Cited by 1,516
Self-citationAsunción, M., Calvo, R. M., San Millán, J. L., Sancho, J., Avila, S., & Escobar-Morreale, H. F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6682 · Cited by 1,318
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Androgen Excess in Women: Experience with Over 1000 Consecutive Patients
Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J., Stephens, K. C., Taylor, K., & Boots, L. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031122 · Cited by 1,132
Self-citation
Cited by
Items 301–400 of 556
Kalhor, M., Mohammadi, E., Shahali, S., Amini, L., & Moghaddam-Banaem, L. (2022) · International Journal of Reproductive BioMedicine (IJRM) · doi:10.18502/ijrm.v20i9.12062 · Cited by 14
“Some women with POCSmay consider their body as ‘different’ because of the PCOS symptoms, i.e., hirsutism.”
BackgroundInfluentialPopovic, M., Monnerat, S., TAYLOR, A. E. R., Gilligan, L. C., Schiffer, L., Arlt, W., Vogt, D., Geyter, C. D., Hutter, N., Donath, M. Y., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1435698 · Cited by 12
“Despite the high prevalence of PCOS, its underlying causes are still unknown, which has substantially limited the development of causative treatments (7, 8).”
Jin, Q., Xu, G. Z., Ying, Y., Liu, L., Zheng, H., Xu, S., Yin, P., & Chen, Y. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01595-5 · Cited by 15
“Its primary diagnostic feature is hyperandrogenism, characterized by elevated serum testosterone levels, hirsutism, acne, oligomenor - rhea or amenorrhea, and an increased number of preant-ral follicles [3].”
Sánchez, G. P., Herrera, R., Pisarska, M. D., Azziz, R., Nicholas, D., & Chan, J. L. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf524 · Cited by 12
Self-citationHealth-Related Behaviors in Women with Lifestyle-Related Diseases
Kozica, S. L., Deeks, A. A., Gibson‐Helm, M. E., Teede, H. J., & Moran, L. (2012) · Behavioral Medicine · doi:10.1080/08964289.2012.685498 · Cited by 17
“26 Research from the Netherlands reports an under-utilization of services by diabetic patients, particularly allied health services including dietitians.”
BackgroundCelik, C., Abalı, R., Güzel, S., Baştu, E., Küçükyalçın, V., & Yılmaz, M. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04437.x · Cited by 12
Polycystic Ovary Syndrome: A Review of Management Outcomes in a Low Resource Setting
GU, E. C. E. (2013) · Journal of Womens Health Issues and Care · doi:10.4172/2325-9795.1000110 · Cited by 15
“Polycystic Ovary Syndrome (PCOS) is the most common endocrinopathy of women within the reproductive age affecting about 6-8% of this age group [1-4].”
Tabrizi, F. P. F., Alipoor, B., Sadaghiani, M. M., Ostadrahimi, A., & Mahdavi, A. M. (2013) · PubMed Central · Cited by 18
Tang, L., Xu, L., Pan, X., Zhang, J., Wu, T., & Liu, G. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008583 · Cited by 12
Sexual orientations of women with polycystic ovary syndrome: Clinical observation in Taiwan
Chen, C.-H., Wang, P., Hsieh, M.-T., Tzeng, C., Wu, Y., Lee, C.-S., Chu, Y.-H., & Chang, H.-Y. (2014) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2014.09.002 · Cited by 12
Low fertility and the risk of type 2 diabetes in women
Elbers, C. C., Onland‐Moret, N. C., Eijkemans, M. J. C., Wijmenga, C., Grobbee, D. E., & van der Schouw, Y. T. (2011) · Human Reproduction · doi:10.1093/humrep/der332 · Cited by 13
“PCOS is a heritable form of ovarian infertility that clinically affects 5–10% of women of reproductive age and is characterized by a long history of chronic anovulation in association with insulin resistance and androgen excess (Azziz et al., 2005, Rotterdam ESHRE/ASRM, 2004).”
BackgroundPourmatroud, E., Mohammadjafari, R., & Roozitalab, M. (2015) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.20082 · Cited by 12
“This disorder is prevalent and affects 5 - 10% of women of reproductive age (2) and causes infertility in 75% of these women due to chronic anovulation (3).”
BackgroundPolycystic ovary syndrome and abnormal glucose tolerance
Teede, H. J., & Stuckey, B. G. A. (2007) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb01271.x · Cited by 11
Polycystic Ovary Syndrome in Active Duty Service Women: A Retrospective Analysis
Hopkins, D., & Wilson, C. (2019) · Military Medicine · doi:10.1093/milmed/usz023 · Cited by 12
Investigation of Prevalence and Awareness of Polycystic Ovary Syndrome among Pakistani Females
Zulfiqar, S., Tahir, S., Gulraiz, S., Razzaq, M. A., Abid, A., Shahid, T., Babar, A., Rehman, B., Rafique, H., Noor, S., et al. (2022) · Proceedings of the Pakistan Academy of Sciences B Life and Environmental Sciences · doi:10.53560/ppasb(59-1)703 · Cited by 23
“The prevalence of PCOS is quite higher in Pakistani women 52 % as compared to western Caucasian women, for instance, 20-25 % in the UK [3-7].”
BackgroundGarcía-Beltrán, C., Malpique, R., Andersen, M., Baş, F., Bassols, J., Darendelıler, F., Díaz, M., Dieris, B., Fanelli, F., Fröhlich-Reiterer, E. E., et al. (2023) · Trials · doi:10.1186/s13063-023-07593-6 · Cited by 13
Vrbíková, J., Hill, M., & Fanta, M. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2014.912265 · Cited by 11
“These conditions contribute significantly to the healthcare-related economical burden for these women [11].”
BackgroundZhang, J., Tang, L., Kong, L., Wu, T., Xu, L., Pan, X., & Liu, G. J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008583.pub2 · Cited by 12
“PCOS results in heavy economic burdens (Azziz 2005).”
BackgroundDemis, A., Kiconco, S., Earnest, A., Khomami, M. B., Dhungana, R. R., Azziz, R., Сутурина, Л. В., Zhao, X., Gambineri, A., Tehrani, F. R., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04221-9 · Cited by 10
“PCOS and its associated health implications generate substantive health [7, 8] and economic burdens for individuals, societies, and governments [9–12].”
Self-citationEvaluation of Ovaries in Patients with Polycystic Ovary Syndrome using Shear Wave Elastography
Altunkeser, A., İnal, Z. Ö., & Baran, N. (2019) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/1573405615666190114150538 · Cited by 10
Polycystic Ovary Syndrome (PCOS ) - A Mini Review
Londonkar, R. (2018) · Open Access Journal of Gynecology · doi:10.23880/oajg-16000148 · Cited by 10
Moderate increases in daily step count are associated with reduced IL6 and CRP in women with PCOS
Webb, M. A., Mani, H., Robertson, S., Waller, H. L., Webb, D. R., Edwardson, C. L., Bodicoat, D. H., Yates, T. E., Khunti, K., & Davies, M. J. (2018) · Endocrine Connections · doi:10.1530/ec-18-0438 · Cited by 12
Suresh, D., Jayaseelan, V., Sulgante, S., Surendran, G., & Roy, G. (2020) · International Journal of Adolescent Medicine and Health · doi:10.1515/ijamh-2020-0108 · Cited by 12
Vine, D. F., Proctor, E., Weaver, O. R., Ghosh, M., Maximova, K., & Proctor, S. D. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab114 · Cited by 11
“These risk factors persist throughout the lifespan of women with PCOS, increasing the risk of cardiovascular disease (CVD), Type 2 Diabetes and other co-morbidities (3-7).”
BackgroundGlueck, C. J., Goldenberg, N., & Wang, P. (2009) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2009.22.9.815 · Cited by 10
“Ibanez et al.(21) recently reported that early metformin therapy in 24 girls, small for geslational age, with precocious puberty and early menarche, prevents progression to PCOS.”
BackgroundIs the Risk for Cardiovascular Disease Increased in all Phenotypes of the Polycystic Ovary Syndrome?
Daskalopoulos, G. N., Karkanaki, A., Karagiannis, A. I., Mikhailidis, D. P., & Athyros, V. G. (2011) · Angiology · doi:10.1177/0003319711399571 · Cited by 10
“Even so, the definition of PCOS has continued to generate significant debate.(6,7) A Position Statement by the Androgen Excess Society (AES) Task Force on the Phenotype of PCOS(8) in 2009 suggested that the original 1990 NIH criteria should be accepted with some modifications.”
BackgroundDiagnosing the diagnosis: why we must standardize the defining features of polycystic ovary syndrome
Azziz, R. (2008) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2007.007198 · Cited by 11
Self-citationPalomba, S., Costanzi, F., Cannarella, R., Votino, R., Calogero, A. E., Signore, F., & Caserta, D. (2025) · Fertility and Sterility · doi:10.1016/j.fertnstert.2025.04.026 · Cited by 9
Liu, M., Cui, J., Chang, H., Liu, J., & Leung, P. C. K. (2025) · Reproduction and Fertility · doi:10.1530/raf-25-0092 · Cited by 9
Zhang, C., Lin, Z., Lin, Y., & Ma, H. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01837-6 · Cited by 9
“The economic impact of PCOS is substantial, arising from direct healthcare costs, productivity losses, and long-term management of associated comorbidities, including obesity, type 2 diabetes mellitus, and cardio-vascular disease [2–4].”
Gorczyca, A. M., Steger, F. L., Ptomey, L. T., Montgomery, R. N., Mickelsen, R., Smith, P. R., Donnelly, J. E., & Marsh, C. A. (2022) · Frontiers in Reproductive Health · doi:10.3389/frph.2022.940945 · Cited by 9
“Primary reasons for exclusion were (1) no longer interested in the study or no response after initial contact (33.”
BackgroundPereira-Eshraghi, C., Tao, R., Chiuzan, C. C., Zhang, Y., Shen, W., Lerner, J. P., Oberfield, S. E., & Sopher, A. B. (2022) · F&S Reports · doi:10.1016/j.xfre.2022.01.008 · Cited by 12
“This small percentage suggests that widespread screening for PCOS is potentially a cost-effective strategy that could lead to earlier diagnosis, intervention, and possibly amelioration and prevention of serious sequelae (34).”
BackgroundHOXA10 expression is decreased by testosterone in luteinized granulosa cells in vitro
Pu, D. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.875 · Cited by 10
Elevated serum interferon γ-inducible protein-10 in women with polycystic ovary syndrome
Deng, H., Li, Z., Liu, G., Li, X., Chen, Y., Zhang, Y., Sun, Y., & Fu, J. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1269740 · Cited by 9
“obesity, type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) [1]; additionally, the economic burden is great to screen for this disorder and treat its lifelong complications [2].”
BackgroundAssessment and Management of Women with Polycystic Ovary Syndrome (PCOS)
Garad, R. M., Shorakae, S., & Teede, H. J. (2019) · Springer eBooks · doi:10.1007/978-3-319-99817-6_39 · Cited by 9
Tear film impairment and meibomian gland loss in patients with polycystic ovary syndrome
Acet, Y., & Sarıkaya, S. (2022) · International Ophthalmology · doi:10.1007/s10792-022-02479-z · Cited by 9
“Prevalence of PCOS has been reported to go up as high as 8% [1].”
BackgroundPalomba, S., Molinaro, M., Ingargiola, A., & Aversa, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2418985 · Cited by 8
“Patients with PCOS frequently undergo diagnostic and therapeutic procedures for reproductive problems [6,9].”
Shetty, B., Shetty, G. B., Nanjeshgowda, H. L., & Shetty, P. (2024) · International Journal of Yoga · doi:10.4103/ijoy.ijoy_180_24 · Cited by 10
“[1] In addition, there is growing evidence that this demographic may be experiencing unfavorable changes in psychosocial functioning.”
Zhang, J., Tang, L., Kong, L., Wu, T., Xu, L., Pan, X., & Liu, G. J. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008583.pub3 · Cited by 9
Wu, L., Zhang, H., Fan, M., & Yan, Y. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/4395612 · Cited by 10
“In addition, PCOS is costly, with an estimated $93 million spent annually on PCOS treatment in the United States, including an average annual cost of $533 million for infertility care [4].”
BackgroundClinical Profile of Patients with Polycystic Ovarian Syndrome in Nepal
Joshi, A. M. (2017) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2017.04.00083 · Cited by 8
“Discussion Clinically diagnosing a woman as having PCOS implies an increased risk for infertility, dysfunctional bleeding, endometrial carcinoma, obesity, Type-II diabetes, hypertension, dyslipidemia, and possibly cardiovascular disease [8].”
BackgroundA Machine Learning Approach for Initial Screening of Polycystic Ovarian Syndrome (PCOS)
Jaralba, J. R., Baldovino, R. G., & Co, H. S. (2021) · Lecture notes in networks and systems · doi:10.1007/978-3-030-66840-2_39 · Cited by 8
Shan, D., Han, J., Cai, Y., Zou, L., Xu, L., & Shen, Y. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab640 · Cited by 9
Acet, Y., & Sarıkaya, S. (2022) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2022.0097 · Cited by 8
Jarrett, B. Y., Lin, A., & Lujan, M. E. (2018) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2018.10.001 · Cited by 8
TRATAMENTO NÃO FARMACOLÓGICO PARA SÍNDROME DOS OVÁRIOS POLICÍSTICOS
Maia, L. O., Furquim, I., Pereira, M., & Vilariño, F. L. (2018) · doi:10.5151/comusc2018-07 · Cited by 7
Joshi, B. N., Shaikh, S. A., Shukla, A., Ganie, M. A., Wani, I. A., Suri, V., Malhotra, N., Agarwal, S., Chowdhury, S., Bhattacharya, P. K., et al. (2024) · Indian Journal of Public Health · doi:10.4103/ijph.ijph_15_23 · Cited by 9
Pace, L. A., Kummer, N., Wallace, M., & Azziz, R. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01702-9 · Cited by 7
“Alternatively, biochemical hyperandrogenism (i.e., hyperandrogenemia) alone correlates poorly with the severity of PCOS symptoms due to these hormones’ cyclic nature, assay quality dependence, and limited test sensitivity and specificity [14].”
InfluentialSelf-citationZhao, J., Ketlhoafetse, A., Liu, X., & Cao, Y. (2022) · Trials · doi:10.1186/s13063-022-06377-8 · Cited by 7
“36 billion [13], resulting in a tremendous economic burden to families and the society as a whole.”
BackgroundGlobal approach to polycystic ovary syndrome in Africa
Sokwala, S. B. M. R., & Dodia, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87932-3.00038-4 · Cited by 9
Coşar, A., Özcan, P., Tanoğlu, F. B., Tok, O. E., Özkara, G., Timur, H. T., Çetin, Ç., & Neccar, D. (2024) · Gynecological Endocrinology · doi:10.1080/09513590.2024.2302086 · Cited by 9
“In 2004, the economic consequences of PCOS in the United States alone exceeded $4 billion, excluding the costs associated with related obstetric problems, T2DM, and other illnesses [6].”
Mani, H., Khunti, K., Daly, H., Barnett, J., & Davies, M. J. (2015) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.4103/1947-489x.210263 · Cited by 8
“5% for PCOS-associated diabetes and the rest for treating menstrual dysfunction/abnormal uterine bleeding, infertility, and hirsutism.(58) Given that up to 69% of”
BackgroundObesity and menstrual disorders
Reavey, J. J., Duncan, W. C., Brito-Mutunayagam, S., Reynolds, R. M., & Critchley, H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817919-2.00019-x · Cited by 9
Melwani, V. (2017) · Indian Journal of Youth and Adolescent Health · doi:10.24321/2349.2880.201717 · Cited by 7
Zhou, J. W., Yang, L., Yu, J., Wang, Y., & Liu, Z. (2017) · Medicine · doi:10.1097/md.0000000000008828 · Cited by 13
Polycystic Ovary Syndrome: Definitions and Epidemiology
Fauser, B. C. J. M., Broekmans, F. J., Laven, J. S. E., Macklon, N., & Tarlatzis, B. C. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-310-3_21 · Cited by 7
Sherif, K., Coborn, J., Hoovler, A., & Gill, L. A. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2140511 · Cited by 9
“4 billion annually between 2005 and 2010 [5,6].”
BackgroundNavigating the Future of PCOS Treatment: The Precision Medicine Paradigm
Sunil, A. T., Jo, C., Sanigha, P. S., Kolasseri, A. E., Tamizhselvi, R., & Jayanthi, S. (2024) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/0118756921331801240820115132 · Cited by 6
Greenwell, S., Jones, A., Smith, Y. R., Marriott, D. J., Aikens, J. E., Padmanabhan, V., & Saslow, L. R. (2024) · Trials · doi:10.1186/s13063-024-08583-y · Cited by 9
“PCOS has a yearly economic burden of 4.3 billion dollars in the USA, 40% of which is due to type 2 diabetes care [6].”
BackgroundInfluential[Polycystic ovary syndrome: is there a rise in the prevalence?].
Io, C.-R., de la Llata, E. S., Sánchez, M. R. M., & Sarrió, A. R. (2015) · PubMed · Cited by 9
Tsikouras, P. N., Deuteraiou, D., Bothou, Α., Anthoulaki, X., Chalkidou, A., Chatzimichael, E., Gaitatzi, F., Manav, B., Koukouli, Z., Zervoudis, S., et al. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15020348 · Cited by 9
Souheil, F. A., & Chahine, B. (2021) · Journal of Health and Allied Sciences NU · doi:10.1055/s-0041-1740025 · Cited by 7
Loverro, G., Pergola, G. D., Naro, E. D., Tartagni, M., Lavopa, C., & Caringella, A. M. (2010) · Journal of Ovarian Research · doi:10.1186/1757-2215-3-25 · Cited by 10
“risk [ 19 ,20]. Previous studies had clearly shown an association between PCOS and carotid intima-media thickness [21] or anteroposterior diameter of infrarenal abdominal aorta [22].”
ResultNamik, J., Alalaf, S., & Tawil, N. A. (2018) · Zanco Journal of Medical Sciences · doi:10.15218/zjms.2018.038 · Cited by 6
“reported acne incidence of 12% - 14% among PCOS women.(16) The findings of this study regarding serum LH and LH/FSH ratio were consistent with”
ResultUltrasonographic prevalence of polycystic ovarian morphology among women of reproductive age group
Jamal, A., Sedeq, M., & Ismael, R. A. (2019) · Zanco Journal of Medical Sciences · doi:10.15218/zjms.2019.008 · Cited by 7
Overview of Long-Term Morbidity and Economic Cost of the Polycystic Ovary Syndrome
Azziz, R. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-179-6_32 · Cited by 7
Self-citationDiabetes advice for women with polycystic ovary syndrome: prevention, prevention, prevention
Mani, H., Khunti, K., Levy, M. J., & Davies, M. J. (2013) · Diabetes Management · doi:10.2217/dmt.13.54 · Cited by 5
Karakurt, F., Çarlıoğlu, A., Kaygusuz, İ., Gümüş, İ. İ., Uz, B., & Akdeniz, D. (2013) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-013-2960-3 · Cited by 5
Hajivandi, L., Noroozi, M., Mostafavi, F., & Ekramzadeh, M. (2018) · Reproductive Health · doi:10.1186/s12978-018-0652-y · Cited by 7
Association between AKT2 gene polymorphism and polycystic ovary syndrome: a case-control study
Li, J., Mo, S., Sun, Y., Huang, H., & Wang, S. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1932800 · Cited by 5
“In the United States, nearly four billion USD is spent in the healthcare system to identify and manage this disease every year [6].”
Background[LH-FSH ratio and Polycystic Ovary Syndrome: A forgotten test?].
de la Llata, E. S., Sánchez, M. R. M., Sarrió, A. R., & Io, C.-R. (2016) · PubMed · Cited by 8
Sylus, A. M., Nandeesha, H., Sridhar, M. G., Thyagaraju, C., & Sreenivasulu, K. (2018) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2018.06.007 · Cited by 5
Polycystic ovary syndrome: An updated review
Priya, M., Nanthini, A., & BINI, K. P. (2019) · International Journal of Health & Allied Sciences · doi:10.4103/ijhas.ijhas_9_19 · Cited by 9
“230 International Journal of Health & Allied Sciences - Volume 8, Issue 4, October-December 2019 account for the disease.[10] Therefore, accurate and early diagnosis of PCOS is necessary not only to prevent future health comorbidities but also to reduce financial cost and burden.”
BackgroundMagnolia officinalis Ameliorates Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome in Rats
Nassar, A., Khachab, M. Y., Zaatiti, H., & Kanaan, A. (2021) · Jundishapur Journal of Natural Pharmaceutical Products · doi:10.5812/jjnpp.106447 · Cited by 5
Hu, X., Zhu, M., Zhou, Q., Li, Z., Luo, L., Liang, W., Chen, S., Pu, X., & Du, J. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s574929 · Cited by 5
Pace, L. A., Waldeck, J., Chan, J. L., Pisarska, M. D., & Azziz, R. (2024) · Journal of Women s Health · doi:10.1089/jwh.2024.0186 · Cited by 5
“8 In addition, less frequent TVUS decreases the need for an intimate portion of the evaluation, which can sometimes be associated with pain or even trauma.”
Self-citationGaray, O. U., Olziersky, A.-M., Laven, J. S. E., Mawson, R. L., Piltonen, T., Franks, S., & Sillman, J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326162 · Cited by 4
“However, previous research has indicated that approximately half of patients with PCOS will seek infertility treatment, with an estimated annual cost of $533 million in 2004 in the United States, indicating that there is a notable cost associated with PCOS-related infertility [40].”
Insulin Ameliorates Folliculogenesis in An Experimental Model of PCOS Mice.
Godaneh, M. H. K., Rahimi, S., Abizadeh, M., Motamedi, S., Younesi, A., Nazarian, H., Gholshan, A., Godaneh, A. K., Aliaghaei, A., Abdi, S., et al. (2023) · PubMed Central · doi:10.22074/ijfs.2022.543499.1228 · Cited by 7
“36 billion dollars was spent every year in the United States of America on the diagnosis and treatment of PCOS, of which more than 40% was spent on the management of developed diabetes mellitus (4).”
BackgroundMandeville, J., Best, D., & Waterman, F. (2021) · Journal of Endometriosis and Pelvic Pain Disorders · doi:10.1177/22840265211024437 · Cited by 4
Polycystic ovary syndrome in North America
Shahid, M., & Wajid, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87932-3.00039-6 · Cited by 5
Obesity and Menstrual Disorders
Critchley, H., Duncan, W. C., Brito-Mutunayagam, S., & Reynolds, R. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416045-3.00038-8 · Cited by 5
A new perspective in diagnosing polycystic ovary syndrome.
Ertörer, M. E., Anaforoğlu, İ., Bozkırlı, E., Bakıner, O., Tütüncü, N. B., & Demirağ, N. G. (2007) · PubMed · Cited by 4
Why we need a stronger focus on women’s health in clinical psychology and psychological treatment
Weise, C., & Gross, C. H. (2024) · Clinical Psychology in Europe · doi:10.32872/cpe.15683 · Cited by 4
“Despite their prevalence and substantial economic burden, these conditions often remain underdiagnosed or untreated (Azziz et al., 2005; Ruszała et al., 2022).”
khansary, S., Yavangi, M., Rabiee, S., Farimani, M., Farhadian, M., Ranjbar, A., Mahmoudi, M., Karimi, M., Barati, S., Mosleh, A. B., et al. (2024) · Journal of Medicine and Life · doi:10.25122/jml-2022-0066 · Cited by 3
“Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, with reported prevalence rates varying be-tween 4% and 25% worldwide, depending on the specific diagnostic criteria used [1-3].”
BackgroundEconomic Burden of Infertility Treatment: A Mini-review on Recent Evidence
Nagajyothi, K. P., Santhosh, A., Dash, S. S., Bhate, J., & Rao, G. K. (2025) · International Journal of Infertility & Fetal Medicine · doi:10.5005/jp-journals-10016-1365 · Cited by 3
Wang, Z., Teng, X., Liu, Y., Shen, Y., Ma, L., & Chen, Y. X. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01975-4 · Cited by 3
Li, Y., Han, L., He, Y., Li, X., Zhang, Y., Zhang, H., Wang, Y., Zhang, H., & Tian, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1627560 · Cited by 3
Balkrishna, A., Rana, M., Mishra, S., Agrawal, R., Rajput, S. K., Dhanasekaran, M., Rana, M., Arya, V., Ramu, R., Upadhayay, A., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1633377 · Cited by 4
Palomba, S., Seminara, G., Costanzi, F., Cannarella, R., Russo, T., Sarica, M., Signore, F., Caserta, D., Calogero, A. E., & Aversa, A. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag102 · Cited by 3
Sharata, E. E., Abdel-Samea, A. S., Ibrahim, L. Y., Mamdouh, M., Khalid, N., Rabea, M., Mohamed, G. H., Abdelnaser, M., & Mohyeldin, R. H. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05559-4 · Cited by 3
“Use the narrow 1990 NIH criteria which demand both hyperandrogenism and oligo-anovulation and prevalence in unselected populations settles around 4–8% (Azziz et al. 2005).”
Mathur, K., Sharma, S., & Hussain, M. S. (2023) · Disease and Diagnosis · doi:10.34172/ddj.2023.508 · Cited by 3
“Conventional statistics suggest a reduction in occurrence, and the expected financial burden of this disorder in Australia was estimated to be AU$ 400 million, indicating the primary impact of obesity on well-being and economic burden (49).”
BackgroundPharmacoeconomic evaluation of treatments for Poly Cystic Ovarian Syndrome (PCOS)
Masroor, D., Khaliq, S. A., Ahmad, S. M., Mazhar, F., & Azhar, I. A. (2024) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-024-00569-6 · Cited by 3
“Highest cost burden is due to management of type-II diabetes in PCOS patients [3].”
BackgroundCallander, E. J., Hu, Y. Y., Carrandi, A., Tay, C. T., Mousa, A., & Teede, H. J. (2025) · International Journal of Women s Health · doi:10.2147/ijwh.s514423 · Cited by 3
“11,12 Of this cost, approximately 46% ($3.9 billion 2022USD) is attributed to the cost of treating reproductive endocrine morbidities—menstrual dysfunction, hirsutism, and infertility care 11 —consistent with the high symptomatology of PCOS during the reproductive years.”
InfluentialKordi, M. R., Motie, Z., Amirsasan, R., & Letafatkar, A. (2011) · Cited by 6
Jain, A., Garg, S., & Sharma, U. (2020) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20200882 · Cited by 4
“Therefore, there should be more widespread and liberal screening as a cost-effective strategy, benefiting earlier diagnosis and intervention and possibly the amelioration and prevention of serious longterm sequel.(8)”
BackgroundBanu, J., Ishrat, S., Deeba, F., Anowary, S., Alamgir, C. F., & Darmini, M. (2021) · Journal of Shaheed Suhrawardy Medical College · doi:10.3329/jssmc.v12i1.51617 · Cited by 4
“[14 Ovulatory disorders in women with PCOS are caused by an increased early follicular growth, resulting in a large reserve of follicles and/or a defective follicular selection, leading to follicular arrest4 Since intra-ovarian andro-gens are also responsible for defective follicular selection and follicular arrest, i…”
BackgroundPersistent risk: psychological comorbidity in polycystic ovary syndrome
Moulana, M. (2020) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2020.08.00297 · Cited by 3
Character strengths of women with polycystic ovary syndrome in a single center
Ghazeeri, G. S., Ibrahim, N., Khalifeh, F., Beyrouthy, C., Taha, L. E., & Bizri, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266398 · Cited by 3
“It is characterized by androgen excess, ovulatory dysfunction, and/or polycystic ovaries which have psychological, economic, and social consequences [2, 3].”
BackgroundThe link between polycystic ovary syndrome and Type 2 diabetes: what do we know today?
Sathyapalan, T., & Atkin, S. L. (2011) · Diabetes Management · doi:10.2217/dmt.11.59 · Cited by 4
Clinical Evaluation of Polycystic Ovary Syndrome
Taylor, A. E. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-310-3_31 · Cited by 3
“... used epidemiologic data and general cost estimates in the United States to estimate the total annual cost of evaluating and providing care to reproductive aged women that pcas in the United States was $4.36 billion, 2.1 % for the initial evaluation, 31 % for hormonally treating menstrual dysfunction/abnormal uteri…”
Influential
Metadata
- Authors
- Azziz, R., Marin, C., Hoq, L., Badamgarav, E., & Song, P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- ORCID
- Azziz, Ricardo
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-08
- Volume
- 90
- Issue
- 8
- Pages
- 4650-4658
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2118575626
- Cited by
- 537
- References
- 90
- Citations by year
- 2026: 20 · 2025: 30 · 2024: 29 · 2023: 28 · 2022: 36 · 2021: 45 · 2020: 25 · 2019: 41 · 2018: 27 · 2017: 27 · 2016: 22 · 2015: 20 · 2014: 27 · 2013: 24 · 2012: 26
- FWCI
- 18.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (K24-D01346)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD029364, R01-HD29364)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- polycystic ovary syndrome, economic burden, health care costs, women of reproductive age, infertility treatment, hirsutism, abnormal uterine bleeding, menstrual disorders, PCOS screening, cost estimation
- MeSH terms
- Adolescent, Adult, Female, Humans, Polycystic Ovary Syndrome, United States, Incidence, Prevalence, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.